Rachel Yehuda

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

Retrieved on: 
Monday, March 29, 2021
Psychiatry, Medical specialties, Post-traumatic stress disorder, Medicine, Aftermath of war, Adverse childhood experiences, Psychiatric diagnosis, Psychedelic therapy, Rachel Yehuda, Complex post-traumatic stress disorder

NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").

Key Points: 
  • NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").
  • The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.
  • Each year, over 8.6 million adults grapple with PTSD, and nearly ten percent of Americans will experience PTSD at some time in their lives.
  • Currently, no academic institution, other than the Center, is conducting research involving the administration of psychedelics inside the VA System.